title: Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis.
authors.forename: Tina Rask
authors.initials: TR
authors.lastname: Elmholdt
authors.forename: Michael
authors.initials: M
authors.lastname: Pedersen
authors.forename: Bettina
authors.initials: B
authors.lastname: Jørgensen
authors.forename: Mette
authors.initials: M
authors.lastname: Ramsing
authors.forename: Anne Braae
authors.initials: AB
authors.lastname: Olesen
mesh_terms: D000328:Adult; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007596:Joints / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D054989:Nephrogenic Fibrosing Dermopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D016059:Range of Motion, Articular; D020127:Recovery of Function; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate